GoodRx Holdings (GDRX) Share-based Compensation (2019 - 2026)

GoodRx Holdings has disclosed Share-based Compensation across 8 years of filings, most recently posting $16.5 million for Q1 2026.

• Share-based Compensation for Q1 2026 came in at $16.5 million, down 13.9% year-over-year; the trailing twelve-month figure through Mar 2026 was $74.0 million (down 20.56% YoY), and the FY2025 annual result was $76.6 million, down 22.62% from the prior year.
• Share-based Compensation came in at $16.5 million for Q1 2026 at GoodRx Holdings, down from $17.9 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $32.6 million in Q3 2023 to a low of $3.6 million in Q2 2022.
• The 5-year median for Share-based Compensation is $21.4 million (2025), against an average of $21.7 million.
• Across the five-year window, Share-based Compensation plunged 35.2% in 2022 and surged 397.14% in 2023, its largest moves.
• GoodRx Holdings' Share-based Compensation stood at $29.4 million in 2022, then decreased by 2.16% to $28.8 million in 2023, then dropped by 27.17% to $21.0 million in 2024, then declined by 14.5% to $17.9 million in 2025, then dropped by 7.87% to $16.5 million in 2026.
• The last three Share-based Compensation figures came in at $16.5 million (Q1 2026), $17.9 million (Q4 2025), and $18.1 million (Q3 2025), per Business Quant data.